Dr. Reddy's Laboratories Limited (RDY) Comparison with companies in other sectors?

Dr. Reddy's Laboratories Limited has a share price of 832.37M. You can analyze Dr. Reddy's Laboratories Limited (RDY) competitors across different market sectors through stock heatmaps.

What are RDY's NET and operating margins?

Dr. Reddy's Laboratories Limited (RDY) operating margin is around 0.22, and net profit margin is approximately 0.17 as of the latest reports.

In what way does RDY's earnings per share (EPS) trend reflect its financial momentum?

Dr. Reddy's Laboratories Limited (RDY) EPS is 0.79 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Dr. Reddy's Laboratories Limited is 18.62, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Dr. Reddy's Laboratories Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Dr. Reddy's Laboratories Limited like P/E which is 18.76, P/B which is 3.18, and PEG which is 0.04. Compare them with sector averages to evaluate if the stock is priced fairly.

Dr. Reddy's Laboratories Limited

RDY•NYSE

Healthcare

Drug Manufacturers - Specialty & Generic

$14.71

$0.11(0.75%)

Fundamental Analysis of Dr. Reddy's Laboratories Limited (RDY)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.79

P/E Ratio

18.62

ROE

0.18%

Net Margin

0.17%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$12.24B

Shares OutstandingTotal number of shares issued

$832.37M

Book Value/ShareNet worth per share

$404.61

Revenue/ShareAnnual revenue per share

$390.65

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.79

Net MarginNet income as percentage of revenue

17.37%

Operating MarginOperating income as percentage of revenue

22.07%

ROEReturn on shareholders' equity

18.08%

ROAReturn on total assets

11.47%

ROCEReturn on capital employed

19.81%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$14.44

Cash/ShareCash and equivalents per share

$69.49

FCF YieldFree cash flow as percentage of market cap

1.14%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$8.27

Dividend YieldAnnual dividend as percentage of stock price

0.65%

Financial Ratios Analysis data is not available for RDYFinancial Ratios Analysis details for RDY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for RDYSector Benchmarking details for RDY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Dr. Reddy's Laboratories Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Dr. Reddy's Laboratories Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Dr. Reddy's Laboratories Limited's unique business strengths and challenges.

Key Financial Metrics for Dr. Reddy's Laboratories Limited

For Dr. Reddy's Laboratories Limited, essential financial indicators include EPS 0.79, PE 18.62, and ROE 0.18. These key ratios reveal insights into Dr. Reddy's Laboratories Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Dr. Reddy's Laboratories Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Dr. Reddy's Laboratories Limited

Metrics like Net Margin 17.37% and ROA 11.47% shed light on how well Dr. Reddy's Laboratories Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Dr. Reddy's Laboratories Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Dr. Reddy's Laboratories Limited

Using ratios such as P/B Ratio 3.18 and PEG Ratio 0.04, investors can assess whether Dr. Reddy's Laboratories Limited is appropriately valued based on its financials and growth potential. These figures, combined with Dr. Reddy's Laboratories Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Dr. Reddy's Laboratories Limited

Financial health indicators, such as Debt/Equity Ratio 0.14 and Cash Flow $14.44, provide a snapshot of Dr. Reddy's Laboratories Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Dr. Reddy's Laboratories Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Dr. Reddy's Laboratories Limited

Investing in Dr. Reddy's Laboratories Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Dr. Reddy's Laboratories Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;